Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 12/2013

Open Access 01-12-2013 | Brief Report

Protection of Chinese painted quails (Coturnix chinensis) against a highly pathogenic H5N1 avian influenza virus strain after vaccination

Authors: Julia Sarkadi, Mate Jankovics, Zoltan Kis, Jozsef Skare, Kinga Fodor, Eva Gonczol, Ildiko Visontai, Zoltan Vajo, Istvan Jankovics

Published in: Archives of Virology | Issue 12/2013

Login to get access

Abstract

Chinese painted quails immunized with a single dose (6 μg HA) of inactivated H5N1 (clade 1) influenza vaccine NIBRG-14 and challenged with 100 LD50 of the heterologous A/Swan/Nagybaracska/01/06(H5N1) (clade 2.2) strain were protected, whereas unvaccinated quails died after challenge. No viral antigens or RNA were detected in cloacal swabs from immunized animals. Sera obtained post-immunization gave low titres in serological assays against the vaccine and the challenge viruses. Our results demonstrate the protective efficacy of the NIBRG-14 strain against the challenge virus and the usefulness of these small birds in protection studies of influenza vaccines.
Literature
1.
Boon ACM, Finkelstein D, Zheng M, Liao G, Allard J, Klumpp K, Webster R, Peltz G, Webby RJ (2011) H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the level of viral load. MBio 2(5): e00171–11. doi:10.​1128/​mBio/​mBio.​00171-11
2.
Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck FD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM (2008) Cross-clade protective immune respomses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1):e1501. doi:10.​1371/​journal.​pone.​0001501 PubMedCrossRef
3.
4.
5.
European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). European Agency for the Evaluation of Medicinal Products, 2004, London, UK
6.
Fazekas G, Martosne-Mendi R, Jankovics I, Szilvásy I, Vajo Z (2009) Cross- reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clin Vaccine Immunol 16:437–443. doi:10.​1128/​CVI.​00327-08 PubMedCrossRef
7.
8.
9.
Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, Suzaki Y, Odagiri T, Tashiro M, Takahashi H, Strayer DR, Carter WA, Chiba J, Tamura S, Sata T, Kurata T, Hasegawa H (2010) Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 82:1754–1761. doi:10.​1002/​jmv.​21824 PubMedCrossRef
10.
11.
Isoda N, Sakoda Y, Kishida N, Bai GR, Matsuda K, Umemura T, Kida H (2006) Pathogenicity of a highly pathogenic avian influenza virus, A/chicken/Yamaguchi/7/04 (H5N1) in different species of birds and mammals. Arch Virol 151:1267–1279. doi:10.​1007/​s00705-005-0723-6 PubMedCrossRef
12.
Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnal WR, Stratov I, Brooks AG, Reading PC, Kent SJ (2013) Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol. doi:10.​4049/​jimmunol.​1201574 PubMed
13.
14.
Kajihara M, Sakoda Y, Soda K, Minari K, Okamatsu M, Takada A, Kida H (2013) The PB2, PA, NP, and NS genes of a highly pathogenic avian influenza virus A/whooper swan/Mongolia/3/2005(H5N1) are responsible for pathogenicity in ducks. Virol J 10:45. doi:10.​1186/​1743-422X-10-45 PubMedCrossRef
15.
16.
Klimov A, Cox N (2003) Serologic diagnosis of influenza virus infections by hemagglutination inhibition. In: Influenza laboratory course. Centers for Disease Control and Prevention, Atlanta, pp 1–5
17.
Lee DH, Park JK, Kwon JH, Yuk SS, Erdene-Ochir TO, Yang YH, Seong BL, Lee JB, Park SY, Choi IS, Song CS (2013) Efficacy of single dose of a bivalent vaccine containing inactivated Newcastle Disease Virus and reassortant highly pathogenic avian influenza H5N1 virus against lethal HPAI an NDV infection in chickens. PLos One 8:e58186. doi:10.​1371/​journal.​pone.​0058186 PubMedCrossRef
18.
Lycett SJ, Ward MJ, Lewis FI, Poon AFY, Kosakovsky Pond SL, Leight Brown AJ (2009) Detection of mammalian virulence determinants in highly pathogenic avian influenza H5N1 viruses: multivariate analysis of published data. J Virol 83:9901–9910. doi:10.​1128/​JVI.​00608-09
19.
20.
Ninomiya A, Imai M, Tashiro M, Odagiri T (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25:3554–3560. doi:10.​1016/​j.​vaccine.​2007.​01.​083 PubMedCrossRef
21.
Nishimura H, Itamura S, Iwasaki T, Kurata T, Tashiro M (2000) Characterization of human influenza A (H5N1) virus infection in mice: neuro-, pneumo- and adipotropic infection. J Gen Virol 81:2503–2510PubMed
22.
23.
Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497
24.
25.
Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya A, Takagi H, Odagiri T, Sata T, Tashiro M, Kobayashi K (2009) Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Inf Dis 199:1629–1637. doi:10.​1086/​598954 CrossRef
26.
27.
Ungchusak K, Auewarakul P, Dowell SE, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmermann JM, Chunsutthhiwat S (2005) Probable person-to-person transmission of avian influenza A (H5N1). N Eng J Med 352:333–340CrossRef
28.
29.
Vajo Z, Wood J, Kosa L, Szilvasy I, Parragh G, Pauliny Z, Bartha K, Visontay I, Kis A, Jankovics I (2010) A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. J Virol 84:1237–1242. doi:10.​1128/​JVI.​01894-09 PubMedCrossRef
30.
31.
32.
Yamada S, Shinya K, Takada A, Ito T, Suzuki T, Suzuki Y, Le QM, Ebina M, Kasai N, Kida H, Horimoto T, Rivailler P, Chen LM, Donis RO, Kawaoka Y (2012) Adaptation of a duck influenza A virus in quail. J Virol 86:1411–1420. doi:10.​1128/​JVI.​06100-11 PubMedCrossRef
33.
Metadata
Title
Protection of Chinese painted quails (Coturnix chinensis) against a highly pathogenic H5N1 avian influenza virus strain after vaccination
Authors
Julia Sarkadi
Mate Jankovics
Zoltan Kis
Jozsef Skare
Kinga Fodor
Eva Gonczol
Ildiko Visontai
Zoltan Vajo
Istvan Jankovics
Publication date
01-12-2013
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 12/2013
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-013-1754-z

Other articles of this Issue 12/2013

Archives of Virology 12/2013 Go to the issue

Original Article

Comparison of genomic and amino acid sequences of eight Japanese encephalitis virus isolates from bats

Original Article

Genetic diversity and mutation of avian paramyxovirus serotype 1 (Newcastle disease virus) in wild birds and evidence for intercontinental spread

Original Article

Genetic properties of endemic Chinese porcine epidemic diarrhea virus strains isolated since 2010

Brief Report

Characterization of signal sequences determining the nuclear export of Newcastle disease virus matrix protein

Annotated Sequence Record

Characterization of a new apscaviroid from American persimmon

Original Article

Genetic structure of rice black-streaked dwarf virus populations in China
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits